Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22766426 | 0.87 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTCNR1CPA1 | |
| SCHEMBL19995541 | 0.75 | VCP (0.33) | VCP | |
| SCHEMBL8472523 | 0.74 | ALDH1A1 (0.44) | ALDH1A1VCPKDM4EMAPTCPA1 | |
| SCHEMBL17048813 | 0.72 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTCNR1MEN1 | |
| SCHEMBL24369781 | 0.69 | CFD (0.33) | KMT2A | |
| SCHEMBL10324344 | 0.69 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL826770 | 0.68 | CES2 (0.45) | ALDH1A1KDM4EMAPTCNR1MEN1 | |
| SCHEMBL17465534 | 0.68 | CES2 (0.45) | ALDH1A1KDM4EMAPTCNR1MEN1 | |
| SCHEMBL6128208 | 0.67 | CNR1 (0.47) | ALDH1A1CNR1CPA1 | |
| SCHEMBL23690690 | 0.67 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTCNR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | BIAL—Portela & Cᵃ, S.A. (PT) | 2021-06-15 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2020-06-11 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| EP-3515917-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018056855-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | ALDH1A1 138/4885VCP 4063/4885KDM4E 3226/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | ALDH1A1 114/4885VCP 4081/4885KDM4E 3244/4885 |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, SLC6A3 | ALDH1A1 70/4885VCP 3848/4885KDM4E 1685/4885 |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, COMT | ALDH1A1 51/4885VCP 3734/4885KDM4E 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.